Overview

A Study of LY3437943 in Chinese Participants With Obesity Or Overweight

Status:
Not yet recruiting
Trial end date:
2023-06-15
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to learn about the safety and tolerability of LY3437943 when given to Chinese participants with overweight body mass index (BMI) or obesity. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injections of LY3437943 or placebo given just under the skin. For each participant, the study will last about 20 weeks excluding screening period and may include up to 20 visits to the study center.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company